Trial Profile
PRODIGE 22-ECKINOXE : Randomized Phase II Trial of Neoadjuvant FOLFOX 4 Versus FOLFOX 4 With Cetuximab Versus Immediate Surgery in Locally Advanced Colon Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Colon cancer
- Focus Therapeutic Use
- Acronyms ECKINOXE; PRODIGE 22; PRODIGE 22-ECKINOXE
- 31 May 2020 At interim analysis, the FOLFOX-cetuximab arm was stopped for futility, according to results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 17 Oct 2017 Status changed from recruiting to active, no longer recruiting, according to results presented at the 42nd European Society for Medical Oncology Congress.